Clinical-stage biotech company Neurizon Therapeutics has developed a new oral liquid formulation of NUZ-001.
The lead investigational therapy is designed for the treatment of amyotrophic lateral sclerosis (ALS), and oral administration will improve the formulation's patient centricity.
By developing a liquid formulation, Neurizon can also improve accessibility for patients who struggle with bulbar onset or difficulty swallowing — which is common in this patient subgroup.
This will allow patients in the advanced stages of disease an alternative to solid dosage forms, which can be hard to manage.
Developed in response to patient and caregiver feedback, the formulation allows for flexible dosing across a range of patient weights and tolerances.
Since the therapeutic can be enterally administered, Neurizon can now ensure that patients receive continuous treatment.
“As ALS progresses, patients face increasing challenges with day-to-day activities, including something as fundamental as swallowing," stated Dr Michael Thurn, Neurizon's' Managing Director and CEO.
"This innovation is about flexibility, inclusion and staying aligned with the needs of people living with ALS. Developing a successful oral liquid formulation — especially for a therapeutic like NUZ-001 targeting a vulnerable patient population — requires careful consideration of physical, chemical and compatibility factors to ensure stability, bioavailability and patient usability."
"By offering NUZ-001 in a liquid form, we’re ensuring that more patients can benefit from the therapy throughout all stages of disease progression.”
The liquid formulation is now being integrated into Neurizon's ongoing clinical development programme for NUZ-001, and will be evaluated for bioequivalence and patient acceptability alongside its tablet form.
